Crossref
Ruxolitinib: JAK2 inhibitor for treatment of myelofibrosis
Future Prescriber · 2012
DOI: 10.1002/fps.100 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Prescriber, 2012. Verfasst von Adam Mead.
Abstract (Originalsprache)
Ruxolitinib is an orally administered JAK2 inhibitor for the treatment of disease‐related splenomegaly or symptoms in primary myelofibrosis or myelofibrosis due to polycythaemia vera or essential thrombocythaemia. In our Drug profile Dr Adam Mead presents the clinical data relating to its efficacy and adverse events and comments on its place in therapy. Copyright © 2013 John Wiley & Sons, Ltd.
Zitieren
APA
Mead, A. (2012). Ruxolitinib: JAK2 inhibitor for treatment of myelofibrosis. Future Prescriber. https://doi.org/10.1002/fps.100
Vancouver
Mead A. Ruxolitinib: JAK2 inhibitor for treatment of myelofibrosis. Future Prescriber. 2012. doi:10.1002/fps.100
BibTeX
@article{Mead2012,
author = {Mead, Adam},
title = {Ruxolitinib: JAK2 inhibitor for treatment of myelofibrosis},
journal = {Future Prescriber},
year = {2012},
doi = {10.1002/fps.100}
}
EUVIMED